Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions
Interventions
KSV01 Injection
Locations
1
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Start Date
September 1, 2025
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2028
Last Updated
April 13, 2026
NCT06090539
NCT07523555
NCT06189391
NCT05006716
NCT06026319
NCT05950165
Lead Sponsor
TCRx Therapeutics Co.Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions